Casticin, a flavonoid isolated from Vitex rotundifolia, inhibits prolactin release in vivo and in vitro

Acta Pharmacologica Sinica

Volumn 31, Issue 12, 2010, Pages 1564-1568

  Ye, Qi ^a   Zhang, Qiao Yan ^a   Zheng, Cheng Jian ^a   Wang, Yang ^a   Qin, Lu Ping ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

casticin; estrogen; estrogen receptors; premenstrual syndrome; prolactin

Indexed keywords

CASTICIN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLAVONOID; MESSENGER RNA; METOCLOPRAMIDE; PROLACTIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG STRUCTURE; FEMALE; HYPERPROLACTINEMIA; HYPOPHYSIS CELL; NONHUMAN; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; RADIOIMMUNOASSAY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; VITEX ROTUNDIFOLIA;

ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; FLAVONOIDS; FRUIT; HYPERPROLACTINEMIA; METOCLOPRAMIDE; PHYTOTHERAPY; PITUITARY GLAND; PLANT EXTRACTS; PROLACTIN; RATS; RATS, SPRAGUE-DAWLEY; VITEX;

EID: 78649919250     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2010.178     Document Type: Article

References (26)

1. Reid RL, Yen SS. The premenstrual syndrome. Clin Obstet Gynecol 1983;26:710-8.
2. Hu Y, Xin HL, Zhang QY, Zheng HC, Rahman K, Qin LP. Anti-nociceptive and anti-hyperprolactinemia activities of Fructus Viticis and its effective fractions and chemical constituents. Phytomedicine 2007;14:668-74.
3. Dickerson LM, Mazyck PJ, Hunter MH. Premenstrual syndrome. Am Fam Physician 2003;67:1743-52.
4. Usman SB, Indusekhar R, O'Brien S. Hormonal management of premenstrual syndrome. Best Pract Res Clin Obstet Gynaecol 2008;22:251-60.
5. Lurie S, Borenstein R. The premenstrual syndrome. Obstet Gynecol Surv 1990;45:220-8.
6. Nagy I, MacLeod RM. Metabolic changes in the rat anterior pituitary and prolactin production following estradiol treatment. Metabolism 1980;29:429-34.
7. Sarkar DK, Hentges ST, De A, Reddy RH. Hormonal control of pituitary prolactin-secreting tumors. Front Biosci 1998;3: d934-43.
8. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000;80:1523-631.
9. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998;338:209-16.
10. Redei E, Freeman EW. Daily plasma estradiol and progesterone levels over the menstrual cycle and their relation to premenstrual symptoms. Psychoneuroendocrinology 1995;20:259-67.
11. Green S, Walter P, Greene G, Krust A, Goffn C, Jensen E, et al. Cloning of the human oestrogen receptor cDNA. J Steroid Biochem 1986;24:77-83.
12. Green S, Walter P, Kumar V, Krust A, Bornert JM, Argos P, et al. Human oestrogen receptor cDNA: sequence, expression and homology to v-erb-A. Nature 1986;320:134-9.
13. Tena-Sempere M, Navarro VM, Mayen A, Bellido C, Sanchez-Criado JE. Regulation of estrogen receptor (ER) isoform messenger RNA expression by different ER ligands in female rat pituitary. Biol Reprod 2004;70:671-8.
14. Hall JM, McDonnell DP. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 1999;140:5566-78.
15. Berger D, Schaffner W, Schrader E, Meier B, Brattstrom A. Effcacy of Vitex agnus castus L extract Ze 440 in patients with pre-menstrual syndrome (PMS). Arch Gynecol Obstet 2000;264:150-3.
16. Lin KC, Kawamura N, Okamura H, Mori T. Inhibition of ovulation, steroidogenesis and collagenolytic activity in rabbits by sulpirideinduced hyperprolactinaemia. J Reprod Fertil 1988;83:611-8.
17. Moro M, Inada Y, Kojima M, Miyata H, Komatsu H, Torii R. New hyperprolactinemia and anovulation model in common marmoset (Callithrix jacchus) and effect of cabergoline. Eur J Pharmacol 1999;368:57-66.
18. Smith RE, Dean PN. A study of acid phosphatase and dipeptidyl aminopeptidase II in monodispersed anterior pituitary cells using flow cytometry and electron microscopy. J Histochem Cytochem 1979;27:1499-504.
19. Seippel L, Backstrom T. Luteal-phase estradiol relates to symptom severity in patients with premenstrual syndrome. J Clin Endocrinol Metab 1998;83:1988-92.
20. Frantz AG. Prolactin. N Engl J Med 1978;298:201-7.
21. Franks S. Regulation of prolactin secretion by oestrogens: physiological and pathological signifcance. Clin Sci (Lond) 1983;65:457-62.
22. Frasor J, Gibori G. Prolactin regulation of estrogen receptor expression. Trends Endocrinol Metab 2003;14:118-23.
23. Jarry H, Leonhardt S, Wuttke W, Spengler B, Christoffel V. Auf der Suche nach dopaminergen Substanzen in Agni-casti-fructus-Präparaten: Warum eigentlich? Z Phytother 1999;20:150-2.
24. Jarry H, Leonhardt S, Gorkow C, Wuttke W. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol 1994;102:448-54.
25. Wuttke W, Jarry H, Christoffel V, Spengler B, Seidlova-Wuttke D. Chaste tree (Vitex agnus-castus) - pharmacology and clinical indications. Phytomedicine 2003;10:348-57.
26. Molitch ME. Medical management of prolactin-secreting pituitary adenomas. Pituitary 2002;5:55-65.